Abstract:
Background: Eventual control of HIV/AIDS is believed to be ultimately dependent on a safe, effective and
affordable vaccine. Participation of sub-Saharan Africa in the conduct of HIV trials is crucial as this region still
experiences high HIV incidences. We describe the experience of recruiting and retaining volunteers in the first
HIV vaccine trial (HIVIS03) in Tanzania.
Methods: In this trial enrolled volunteers from amongst Police Officers (POs) in Dar es Salaam were primed
with HIV-1 DNA vaccine at months 0, 1 and 3; and boosted with HIV-1 MVA vaccine at months 9 and 21. A
stepwise education provision/sensitization approach was employed to eventual recruitment. Having identified
a “core” group of POs keen on HIV prevention activities, those interested to participate in the vaccine trial
were invited for a first screening session that comprised of provision of detailed study information and
medical evaluation. In the second screening session results of the initial assessment were provided and those
eligible were assessed for willingness to participate (WTP). Those willing were consented and eventually
randomized into the trial having met the eligibility criteria. Voluntary participation was emphasized throughout.
Results: Out of 408 POs who formed the core group, 364 (89.0%) attended the educational sessions. 263 out of 364
(72.2%) indicated willingness to participate in the HIV vaccine trial. 98% of those indicating WTP attended the
pre-screening workshops. 220 (85.0%) indicated willingness to undergo first screening and 177 POs attended for initial
screenings, of whom 162 (91.5%) underwent both clinical and laboratory screenings. 119 volunteers (73.5%) were
eligible for the study. 79 were randomized into the trial, while 19 did not turn up, the major reason being partner/
family advice. 60 volunteers including 15 females were recruited during a one-year period. All participated in the
planned progress updates workshops. Retention into the schedule was: 98% for the 3 DNA/placebo vaccinations, while
it was 83% and 73% for the first and second MVA/placebo vaccinations respectively.
Conclusion: In this first HIV vaccine trial in Tanzania, we successfully recruited the volunteers and there was no
significant loss to follow up. Close contact and updates on study progress facilitated the observed retention rates.
